MedTrace Logo

Clinical Study to Evaluate Efficacy and Safety of DA-1229 in Patients With CAVD

NCT04055883 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 228

Last updated 2023-03-03

No results posted yet for this study

Summary

This study will evaluate the efficacy and safety of DA-1229 in patients with calcific aortic valve disease.

Conditions

  • Calcific Aortic Valve Disease

Interventions

DRUG

DA-1229

All participants are administered one tablet per day for 96 weeks

Sponsors & Collaborators

  • Dong-A ST Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-08-26
Primary Completion
2023-02-01
Completion
2023-02-01

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04055883 on ClinicalTrials.gov